Joseph F Levy1, Rahul Khairnar2, Alexander V Louie3, Timothy N Showalter4, C Daniel Mullins2, Mark V Mishra5. 1. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland. 3. London Health Sciences Centre, London, Ontario, Canada. 4. Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia. 5. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: mmishra@umm.edu.
Abstract
PURPOSE: A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT). METHODS AND MATERIALS: A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted. RESULTS: The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively. CONCLUSIONS: Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making.
PURPOSE: A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT). METHODS AND MATERIALS: A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted. RESULTS: The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively. CONCLUSIONS: Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making.
Authors: Scott C Lester; Laura A McGrath; Rachael M Guenzel; Jenae C Quinn; Carolyn J Schultz; T Baron Bradley; Bret D Kazemba; Shima Ito; Christopher L Hallemeier Journal: Int J Part Ther Date: 2022-04-26
Authors: Rahul Khairnar; Stephanie L Pugh; Howard M Sandler; W Robert Lee; Ester Villalonga Olives; C Daniel Mullins; Francis B Palumbo; Deborah W Bruner; Fadia T Shaya; Soren M Bentzen; Amit B Shah; Shawn C Malone; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; Michele Albert; Adam D Currey; Thomas M Pisansky; Yuhchyau Chen; Eric M Horwitz; Albert S DeNittis; Felix Y Feng; Mark V Mishra Journal: PLoS One Date: 2021-04-14 Impact factor: 3.240
Authors: Michael C Repka; Michael Creswell; Jonathan W Lischalk; Michael Carrasquilla; Matthew Forsthoefel; Jacqueline Lee; Siyuan Lei; Nima Aghdam; Shaan Kataria; Olusola Obayomi-Davies; Brian T Collins; Simeng Suy; Ryan A Hankins; Sean P Collins Journal: Front Oncol Date: 2022-03-31 Impact factor: 6.244
Authors: William A Hall; Alison C Tree; David Dearnaley; Christopher C Parker; Vinay Prasad; Mack Roach; Colleen A F Lawton Journal: Lancet Oncol Date: 2021-01 Impact factor: 41.316
Authors: James D Byrne; Cameron C Young; Jacqueline N Chu; Jennifer Pursley; Mu Xian Chen; Adam J Wentworth; Annie Feng; Ameya R Kirtane; Kyla A Remillard; Cindy I Hancox; Mandar S Bhagwat; Nicole Machado; Tiffany Hua; Siddartha M Tamang; Joy E Collins; Keiko Ishida; Alison Hayward; Sarah L Becker; Samantha K Edgington; Jonathan D Schoenfeld; William R Jeck; Chin Hur; Giovanni Traverso Journal: Adv Sci (Weinh) Date: 2021-04-27 Impact factor: 16.806
Authors: Michael Yan; Andre G Gouveia; Fabio L Cury; Nikitha Moideen; Vanessa F Bratti; Horacio Patrocinio; Alejandro Berlin; Lucas C Mendez; Fabio Y Moraes Journal: Nat Rev Urol Date: 2021-08-13 Impact factor: 14.432